TABLE 1.
Baseline characteristics of patients
| Type of chemotherapy | Paclitaxel‐bevacizumab | Paclitaxel | Pemetrexed | Gemcitabine | ||||
|---|---|---|---|---|---|---|---|---|
| n = 57 | n = 35 | n = 21 | n = 39 | |||||
| n = 152 | CAI | CWPI | CAI | CWPI | CAI | CWPI | CAI | CWPI |
| (n = 34) | (n = 23) | (n = 24) | (n = 11) | (n = 6) | (n = 15) | (n = 27) | (n = 12) | |
| Median age (years) (Q1–Q3) | 57.5 (53–62) | 59 (50–65) | 63 (53.5–67) | 70 (65.5–79) | 61 (68.5–70.2) | 66 (60.5–72.5) | 61 (58.5–66) | 64.5 (56.8–70.5) |
| Male Gender | 22 (64.7) | 16 (69.6) | 15 (62.5) | 7 (63.6) | 3 (50) | 7 (46.7) | 19 (70.4) | 5 (41.7) |
| Smoking status | ||||||||
| Never | 2 (5.9) | 1 (4.3) | 0 (0) | 1 (9.1) | 0 (0) | 4 (26.7) | 2 (7.4) | 2 (16.7) |
| Former | 28 (82.4) | 15 (65.2) | 19 (79.2) | 9 (81.8) | 6 (100) | 6 (40) | 20 (74.1) | 6 (50) |
| Current | 4 (11.8) | 7 (30.4) | 5 (20.8) | 1 (9.1) | 0 (0) | 5 (33.3) | 5 (18.5) | 4 (33.3) |
| Histologic subtype | ||||||||
| Adenocarcinoma | 33 (97.5) | 23 (100) | 15 (62.5) | 7 (63.6) | 6 (0) | 12 (80) | 14 (51.9) | 6 (50) |
| Squamous | 0 (0) | 0 (0) | 8 (33.3) | 3 (27.3) | 0 (0) | 1 (6.7) | 12 (44.4) | 6 (50) |
| Other | 1 (2.9) | 0 (0) | 1 (4.2) | 1 (9.1) | 0 (0) | 2 (13.3) | 1 (3.7) | 0 (0) |
| Line of chemotherapy of interest | ||||||||
| 1 | 0 (0) | 0 (0) | 0 (0) | 9 (81.8) | 0 (0) | 6 (40) | 0 (0) | 2 (16.7) |
| 2 | 2 (5.9) | 21 (91.3) | 2 (8.3) | 2 (18.2) | 0 (0) | 8 (53.3) | 1 (3.7) | 4 (33.3) |
| ≥3 | 32 (94.1) | 2 (8.7) | 22 (91.7) | 0 (0) | 6 (100) | 1 (6.7) | 26 (96.3) | 6 (50) |
| Median number of lines received (range) | 3.5 (3–7) | 2 (2–4) | 3 (2–6) | 2 (1–2) | 4 (3–5) | 2 (1–3) | 4 (2–6) | 3 (1–5) |
| PD‐L1 status a | ||||||||
| <1% | 14 (41.2) | 15 (65.2) | 9 (37.5) | 1 (9.1) | 1 (16.7) | 5 (33.3) | 9 (33.3) | 1 (8.3) |
| 1%–49% | 8 (23.5) | 3 (13.0) | 6 (25) | 3 (27.3) | 4 (66.7) | 5 (33.3) | 7 (25.9) | 1 (8.3) |
| >50% | 5 (14.7) | 0 (0) | 4 (16.7) | 2 (18.2) | 1 (16.7) | 0 (0) | 4 (14.8) | 2(16.6) |
| Unknown | 7 (20.6) | 5 (21.8) | 5 (20.8) | 5 (45.4) | 0 (0) | 5 (33.3) | 7 (25.9) | 8 (66.6) |
| EGFR (%) | 0 (0) | 1 (4.5) | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 1(3.7) | 0 (0) |
| ALK (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| KRAS (%) | 14 (41.2) | 7 (30.4) | 5 (20.8) | 3 (27.2) | 3 (50) | 4 (26.7) | 8 (29.6) | 2 (16.7) |
| BRAF (%) | 2 (5.8) | 4 (17.4) | 1 (4.1) | 1 (9) | 0 (0) | 1 (6.7) | 1 (3.7) | 0 (0) |
| ROS (%) | 1 (2.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| STK11 (%) | 2 (5.8) | 1 (14.3) | 4 (16.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ECOG PS b | ||||||||
| ≤1 | 27 (79.4) | 11 (47.8) | 8 (33.3) | 4 (36.4) | 4 (66.6) | 8 (53.3) | 15 (55.6) | 4 (33.3) |
| >1 | 7 (20.6) | 12 (52.1) | 16 (66.6) | 7 (63.6) | 2 (33.3) | 7 (46.7) | 12 (44.4) | 8 (66.7) |
| Type of ICI | ||||||||
| Nivolumab | 17 (50) | – | 8 (33.3) | – | 3 (50) | – | 16 (59.3) | – |
| Pembrolizumab | 11 (32.4) | 8 (33.3) | 2 (2) | 3 (11.1) | ||||
| Atezolizumab | 6 (17.6) | 7 (29.1) | 1 (16.7) | 8 (29.6) | ||||
| Other | 0 (0) | 1 (4.2) | 0 (0) | 0 (0) | ||||
| Presence of brain metastasis b | 23 (67.6) | 11 (47.8) | 10 (41.7) | 3 (27.3) | 1 (16.7) | 6 (40) | 8 (29.6) | 5 (41.7) |
| Presence of liver metastasis b | 9 (26.5) | 6 (26.1) | 10 (41.7) | 1 (9.1) | 2 (33.3) | 1 (6.7) | 5 (18.5) | 4 (33.3) |
| Interstitial lung disease at the diagnostics | 1 (2.9) | 0 (0.0) | 0 (0.0) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 1 (3.7) | 0 (0.0) |
Note: Data are shown as n (%); medians are defined with their with first and third quartiles or range.
Abbreviations: CAI, chemotherapy of interest after ICI; CWPI, chemotherapy regimen without previous ICI; ECOG PS, Eastern Cooperative Oncology Group performance‐status scores; ICI, immune checkpoint inhibitor. Q1–Q3, quartile 1‐quartile 3.
a
Determined by immunohistochemistry.
b
At the initiation of the studied chemotherapy.